Don't hesitate to send a message
Founded in 1987, Zhejiang INI Medical Devices Co., Ltd. is a professional company registered by the State Food and Drug Administration to produce sterile medical device products such as disposable insulin syringes. With the increasing demand in the market from 2009 to 2019, the company has continued expanding the production scale, investing more than 100 million RMB in the construction of a new factory in Wenzhou Yongqiang High-tech Park, with a total construction area of about 26,000㎡, of which 100,000 clean workshops are about 8,000㎡.
We possess advanced production equipment, well-appointed production sites, capacious storage sites, and a favorable clean production environment that adapts to the production of medical equipment products and production scale. We have a perfect quality management system, and carry on extremely strict control of each link in the production chain. We are equipped with sound and qualified inspection institutions, complete and functional inspection methods, and outstanding inspection capability appropriate to the production scale.
The company established a quality assurance system according to YY/T0287-2017 IDT IS013485-2016, passed the internationally renowned TUV company international quality system certification, and obtained the CE mark certificate issued by the European Community.
The company insists on continuous innovation, continuous improvement, and better meeting the requirements of laws and regulations and customers, and strives to become a well-known manufacturer with a good corporate image and brand reputation in the industry. The general manager of the company sincerely welcomes domestic and foreign medical institutions and medical units to cooperate with us and join hands to contribute to the cause of human health.
INI has published a technical report on insulin delivery devices, outlining industry advancements and sharing practical insights in precision molding and needle tip processing.
Read moreTo meet market demand, INI has begun expanding its production base with an additional 800㎡ 100,000-class cleanroom. The facility is expected to operational in Q4 2025, increasing capacity by 30%.
Read moreINI has successfully passed its annual ISO 13485 quality management system audit. The certification body recognized its production environment control, processes, and traceability systems.
Read moreINI will exhibit at the 2025 International Diabetes Congress in Shanghai, sharing technological advancements in insulin delivery devices. A product experience zone will be available for professional e...
Read moreAt Medical Asia 2025, INI's newly launched ultra-thin wall insulin syringe attracted notable interest. The innovative design maintains delivery efficiency while improving user comfort.
Read moreINI participated in MEDICA 2025, presenting its latest insulin injection solutions. The booth featured EU-compliant disposable insulin syringe series, drawing significant attention from professional v...
Read more